Here is the letter from leading AIDS advocacy organizations sent to the FDA supporting a prevention indication for Truvada. IRMA is a co-signer,and supporter of these efforts.

The FDA will be reviewing Gilead’s application for Truvada as PrEP on Thursday, May 10. Stay abreast of the developments on the PrEP Watch website.

Click here for the FDA’s Antiviral Drugs Advisory Committee agenda, committee roster, etc for the review of Truvada as PrEP on May 10.

Click to enlarge.


*Join IRMA’s robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at Joining our listserv automatically makes you a member of IRMA – a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article’s content.